Weeks after FDA delay, Roche, PTC unveil another batch of positive risdiplam data in severe SMA patients
While the FDA has decided it needs another quarter to review Roche and PTC Therapeutics’ oral SMA therapy, its makers are reporting a steady drumbeat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
